NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a distribution agreement with IPS Genomix for its SelectMDx for Prostate Cancer test in the Middle East.

IPS Genomix will distribute the test in Lebanon, Egypt, the United Arab Emirates, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan. The company will also handle reimbursement for SelectMDx within the Middle East. MDxHealth, meanwhile, will perform the SelectMDx testing service in its ISO-certified clinical diagnostic laboratory in Nijmegen, the Netherlands.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.